← All trials
NCT04349761
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 11, 2019
- Primary completion
- Dec 30, 2019
- Completion date
- Dec 30, 2019
- First posted
- Apr 16, 2020
- Last posted
- Apr 16, 2020
- Enrollment
- 40
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- MyMD Pharmaceuticals, Inc.Lead sponsor
- Clinical Research of West FloridaOverall official - principal investigator
- Palm Beach CRO, LLCStudy director
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.